Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
NVZMY US​

Novozymes As/fi American Depositary Receipt(NVZMY US)

$71.93+0.120.17%Ext:$71.88-0.050.07%(Market Closed · 20:00:00 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Novozymes As/fi American Depositary Receipt — Company Profile

Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company's broad range of products caters to numerous sectors: Food and Beverages: Supplying ingredients and processing aids for baking, a variety of beverages, dairy production, starch modification, and protein applications. Household Care: Delivering specialized formulations for laundry, dishwashing, and professional cleaning solutions. Agriculture: Providing innovations for crop cultivation, animal health and nutrition, alongside bioyield and biocontrol products for plant growth. Bioenergy and Industrial Processing: Offering critical components for grain and technical processing, encompassing liquefaction, saccharification, fermentation, fiber conversion, and biomass transformation. Textiles: Featuring technologies for biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing. Pulp and Paper: Enhancing processes through fiber modification, bleach boosting, deposit control, starch modification, and deinking agents. Leather Production: Furnishing treatments for acid bating, area expansion, general bating, degreasing, soaking, and unhairing/liming stages. Water and Waste Management: Contributing with bioaugmentation strategies, optimization of biogas production, and sludge management. Pharmaceuticals: Supplying specialized lipases (both free and immobilized), proteases for biocatalysis, and rTrypsin vital for cell culture applications. Furthermore, Novozymes provides offerings related to human health and various protein-based products. Founded in 1925, Novozymes A/S is headquartered in Bagsvaerd, Denmark.

Sector
Industrials
Industry
Professional Services
Exchange
UU
CEO
Ester Baiget
Headquarters
Lyngby, G7, DK
IPO Date
Jan 20, 2010
Employees
11,641
Website
www.novonesis.com

Key Metrics

Price
$62.60
Market Cap
$29.19B
Revenue (TTM)
$1.14B
Net Income (TTM)
$202.37M
EPS (TTM)
0.43
P/E (TTM)
-101.13
P/B (TTM)
2.67
Dividend Yield
1.76%
ROE (TTM)
1.85%
ROA (TTM)
1.22%
Operating Margin
23.98%
Beta
0.01

Dividends

Last Dividend
$0.65
Last Yield
0.02%

Summary

Novozymes A/S is a global biotechnology firm that specializes in the creation and distribution of industrial enzymes, microorganisms, and probiotics. Its operational footprint spans across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company's broad range of products caters to numerous sectors: Food and Beverages: Supplying ingredients and processing aids for baking, a variety of beverages, dairy production, starch modification, and protein applications. Household Care: Delivering specialized formulations for laundry, dishwashing, and professional cleaning solutions. Agriculture: Providing innovations for crop cultivation, animal health and nutrition, alongside bioyield and biocontrol products for plant growth. Bioenergy and Industrial Processing: Offering critical components for grain and technical processing, encompassing liquefaction, saccharification, fermentation, fiber conversion, and biomass transformation. Textiles: Featuring technologies for biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing. Pulp and Paper: Enhancing processes through fiber modification, bleach boosting, deposit control, starch modification, and deinking agents. Leather Production: Furnishing treatments for acid bating, area expansion, general bating, degreasing, soaking, and unhairing/liming stages. Water and Waste Management: Contributing with bioaugmentation strategies, optimization of biogas production, and sludge management. Pharmaceuticals: Supplying specialized lipases (both free and immobilized), proteases for biocatalysis, and rTrypsin vital for cell culture applications. Furthermore, Novozymes provides offerings related to human health and various protein-based products. Founded in 1925, Novozymes A/S is headquartered in Bagsvaerd, Denmark.

Website
www.novonesis.com
Location
Lyngby, G7, DK
Phone45 44 46 00 00
Employees11,641
CEOEster Baiget
Sector
Industrials
Industry
Professional Services
IPO DateJan 20, 2010

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(71)

Expand
  • F-6 POSPost-effective amendment (depository shares)1 Apr 2024
  • F-6 POSPost-effective amendment (depository shares)27 Mar 2024
  • F-6 POSPost-effective amendment (depository shares)19 Mar 2024
  • F-6EFEffective registration statement (depository shares)22 Nov 2019
  • F-6 POSPost-effective amendment (depository shares)29 Sep 2017
  • F-6EFEffective registration statement (depository shares)2 Jun 2010
  • F-6EFEffective registration statement (depository shares)16 Mar 2010
  • ARSAUTO-GENERATED PAPER DOCUMENT24 Feb 2009
  • ARSAUTO-GENERATED PAPER DOCUMENT25 Feb 2008
  • SUPPLAUTO-GENERATED PAPER DOCUMENT13 Feb 2008
  • F-6EFEffective registration statement (depository shares)14 Aug 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT25 Jun 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT14 Jun 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT2 May 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT23 Apr 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT18 Apr 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT15 Mar 2007
  • ARSAUTO-GENERATED PAPER DOCUMENT27 Feb 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT27 Feb 2007
  • SUPPLAUTO-GENERATED PAPER DOCUMENT20 Feb 2007

News

  • Financial Analysis: Novozymes A/S (OTCMKTS:NVZMY) vs. Neo Performance Materials (OTCMKTS:NOPMF)6 Oct
  • FUL or NVZMY: Which Is the Better Value Stock Right Now?24 Aug
  • Novozymes A/S (NVZMY) Q2 2026 Earnings Call Transcript20 Aug
  • FUL vs. NVZMY: Which Stock Is the Better Value Option?7 Aug

Mentions in Filings

  • #Novo Nordisk A/S, Class B, Sponsored ADR 55,018 3,269,720 Novonesis Novozymes B, Class B 124,202 7,631,541
    Dimensional ETF TrustNovozymes As/fi American Depositary Receipt·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • issuer are subject to the repurchase agreement, those securities may be aggregated in responding to Items C.10.f.i-iii. Item C.11. For derivatives, also provide: Item C.12. Securities lending. a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No c. Is any port …
    Dimensional ETF TrustNovozymes As/fi American Depositary Receipt·NPORT-P - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … 10 SEDOL : 4588825 105,242.000 2,531,460.25 2,976,810.07 NKT A/S SEDOL : 7106354 15,692.000 1,201,715.27 1,121,075.04 NOVO NORDISK A/S SER'B'DKK0.1 SEDOL : BP6KMJ1 31,974.000 2,249,338.49 2,771,352.31 <strong>NOVONESIS (NOVOZYMES) B</strong> SEDOL : B798FW0 20,952.000 1,240,270.95 1,186,143.41 Total Denmark - DKK 7,222,784.96 8,055,380.83 Denmark - USD ADR NOVO-NORDISK A S ADR SEDOL : 2651202 4,057.000 283,621.56 348,983.14 Total Denmark - …
    UBS Group AGNovozymes As/fi American Depositary Receipt·11-K - Annual report (employee stock purchase/savings/profit sharing plans)·FY24·26 Jun 2025
  • … | | | | (78,864,790,583) | | | Norway | AKER BP ASA | 15,968,056 | 314.20 | 5,017,163,195.20 | | | Krone | Norwegian Krone Subtotal | 15,968,056 | | 5,017,163,195.20 | | | | | | | (83,585,938,832) | | | Denmark | <strong>NOVONESIS (NOVOZYMES) B</strong> | 10,134,094 | 390.80 | 3,960,403,935.20 | | | Krone | Danish Krone Subtotal | 10,134,094 | | 3,960,403,935.20 | | | | | | | (97,861,581,238) | | | Hong Kong Dollar | AIA GROUP | 128,725,800 | 74.25 | 9,557,890,65 …
    インベスコ・アセット・マネジメント株式会社Novozymes As/fi American Depositary Receipt·Annual Report - Annual Securities Report (2025.12.23-2026.06.23)·17 Sep·16 Sep
  • … | | | | (78,864,790,583) | | | Norway | AKER BP ASA | 15,968,056 | 314.20 | 5,017,163,195.20 | | | Krone | Norwegian Krone Subtotal | 15,968,056 | | 5,017,163,195.20 | | | | | | | (83,585,938,832) | | | Denmark | <strong>NOVONESIS (NOVOZYMES) B</strong> | 10,134,094 | 390.80 | 3,960,403,935.20 | | | Krone | Danish Krone Subtotal | 10,134,094 | | 3,960,403,935.20 | | | | | | | (97,861,581,238) | | | Hong Kong Dollar | AIA GROUP | 128,725,800 | 74.25 | 9,557,890,65 …
    インベスコ・アセット・マネジメント株式会社Novozymes As/fi American Depositary Receipt·Prospectus - Amended Securities Registration Statement·17 Sep·16 Sep
  • … | America | stock | TRACTOR SUPPLY COMPANY | Distribution and retail of general consumer goods and services | 21,227,930 | 4,873.60 | 103,456,560,395 | 5,066.56 | 107,552,750,844 | 2.36 | | 13 | Denmark | stock | <strong>NOVONESIS (NOVOZYMES) B</strong> | material | 10,593,222 | 9,703.41 | 102,790,479,061 | 10,108.47 | 107,081,372,722 | 2.35 | | 14 | America | stock | UNION PACIFIC | transportation | 2,417,602 | 42,206.78 | 102,039,207,588 | 44,283.75 | 107,060,4 …
    インベスコ・アセット・マネジメント株式会社Novozymes As/fi American Depositary Receipt·Prospectus - Securities registration statement·16 Sep·15 Sep

Key Stats

Trading

Px/Chg 1D$62.60 / +0.71%
Avg Volume95.41K
Beta0.01
Mkt Cap29.19B
FD Mkt Cap33.52B

Float

Shrs Out/Float466.23M / 344.43M
Short Float0.00%
Days to Cover1.00
Stock Repurchased$0.00

Current Valuation

EV32.07B
EV/EBITDA25.72
EV/Sales7.61
P/B2.67
P/S6.93
FCF Yield0.31%
ROE1.85%
ROA1.22%
Current Ratio1.67

Dividend

Cash$0.65
Yield1.76%
Yield (TTM)1.76%

Estimates

P/E-101.13
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Mar '26Oct '26
PRICE-BASED RATIOS
Price / Earnings34.873.875.4153.22-32.37144.22
Price / Sales11.300.810.914.2524.8525.65
Price / Book Value1.721.031.171.462.282.67
Price / Free Cash Flow123.1012.757.8124.65244.02326.29
ENTERPRISE VALUE METRICS
Enterprise Value26,763.113,985.623,026.717,790.746,938.532,074.0
Enterprise Value / Sales16.400.801.294.6447.1028.19
Enterprise Value / EBITDA51.502.294.212.20173.3275.47
Enterprise Value / EBIT78.253.005.642.83262.19117.57

Financials

Full Financials
Millions EUR5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue-27.4%14,951.017,553.017,899.03,833.54,157.6
Gross Income-28.6%8,623.09,577.09,722.01,809.52,241.5
EBITDA-28.8%5,400.06,115.05,471.08,071.01,386.5
EBIT-33%4,026.04,658.04,082.06,286.3811.7
Net Income-34.4%3,146.03,676.03,024.0305.8583.6
EPS (Diluted)-42.2%11.2313.191.461.101.25
BALANCE SHEET
Cash & ST Inv-26.9%1,038.01,121.01,116.0284.0295.6
Total Assets-9.9%24,767.027,983.028,391.015,195.616,349.1
Total Liabilities-18.7%12,561.013,755.014,040.04,019.65,493.9
Total Shareholder Equity-2.1%11,827.013,837.013,978.011,176.010,855.2
CASH FLOW
Net Operating Cash Flow-25.9%4,062.04,006.04,152.01,019.91,221.5
Cap Ex-21.5%-1,240.0-2,890.0-2,056.0-359.8-470.8
Free Cash Flow-28.2%2,822.01,116.02,096.0660.1750.7

Enterprise Value Bridge

Millions EUR23 Oct '26
Price (As of 23 Oct '26)71.86
Basic Shares466.23
Market Cap33,503.0
Diluted Shares466.23
Fully Diluted Shares Outstanding466.23
Fully Diluted Market Cap33,503.0
+Consolidated Debt3,215.7
−In-the-Money Convertible Debt—
+Capital Leases-
+Operating Leases—
−Cash & Equivalents-327.5
−Short-term Investments-2.2
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value36,391.1

Related companies

Iqvia Holdings Inc.

IQV US

Wanhua Chemical Group Co., Ltd.

600309 CG

DSM-Firmenich AG/ADR

DSFIR NA

L Air Liquide Sa /FI

AIQUY US

EMS-Chemie Holding AG/ADR

EMSHF US

Incyte Corp

INCY US

Grace Fabric Technology Co.,Ltd.

603256 CG

Medpace Holdings, Inc.

MEDP US

Nippon Paint Holdings Co., Ltd.

NPCPF US

Covestro AG/ADR

COVTY US

Symrise AG

SYIEY US

Charles River Laboratories International, Inc.

CRL US

Financials & Metrics

FinancialsChartingShort InterestEmployees